On September 3, 2026 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, reported that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings during the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ms. Zannes’ presentation will feature recent and upcoming strategic milestones, commercial adoption and momentum for the Company’s CyPath Lung diagnostic test, and advancements for the proprietary technology platform to develop additional diagnostic and therapeutic applications.

Institutional investors can register here to attend the conference virtually or in-person at the Lotte New York Palace Hotel. Registered investors may request a meeting via the conference website.

A live and archived webcast of the bioAffinity presentation will be available on September 11 at https://bit.ly/BIAFPresentation.

(Press release, BioAffinity Technologies, SEP 3, 2026, View Source [SID1234670585])